Mayne Pharma’s drug development pipeline is focused on novel therapies that could provide meaningful benefit to patients.
Programs with Orphan Designations
SUBA-itraconazole for the treatment of basal cell carcinoma nevus syndrome (BCCNS), also known as Gorlin Syndrome
BCCNS/Gorlin Syndrome is a rare disease with unmet medical need. Patients develop recurrent basal cell carcinomas that may require surgery. The basal cell carcinomas in BCCNS exhibit up-regulation of the Hedgehog signaling pathway. SUBA® - itraconazole, the novel formulation of itraconazole developed by Mayne Pharma, is being studied in this indication. We believe that itraconazole is an inhibitor of the Hedgehog signalling pathway, and SUBA® - itraconazole may enable more predictable absorption possibly resulting in improved bioavailability and more consistent pharmacokinetics than conventional formulations of itraconazole.
Trifarotene for the treatment of lamellar ichthyosis
Lamellar ichthyosis is a rare dermatological disorder with unmet medical need. It is a type of autosomal recessive congenital ichthyosis. Trifarotene, a novel retinoid acid receptor-γ (RARγ) agonist, is being studied for this indication.